179 related articles for article (PubMed ID: 33652263)
1. Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours.
Desnoyers A; Wilson BE; Nadler MB; Amir E
Cancer Treat Rev; 2021 Mar; 94():102167. PubMed ID: 33652263
[TBL] [Abstract][Full Text] [Related]
2. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Wilson BE; Desnoyers A; Nadler MB; Tibau A; Amir E
Cancer Med; 2021 Aug; 10(16):5405-5414. PubMed ID: 34323019
[TBL] [Abstract][Full Text] [Related]
3. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis.
Del Paggio JC; Tannock IF
Lancet Oncol; 2019 Aug; 20(8):1065-1069. PubMed ID: 31296490
[TBL] [Abstract][Full Text] [Related]
4. Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis.
Huang X; Chen B; Thabane L; Adachi JD; Li G
Osteoporos Int; 2021 Sep; 32(9):1713-1723. PubMed ID: 33595680
[TBL] [Abstract][Full Text] [Related]
5. Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index.
Gaudino M; Hameed I; Biondi-Zoccai G; Tam DY; Gerry S; Rahouma M; Khan FM; Angiolillo DJ; Benedetto U; Taggart DP; Girardi LN; Crea F; Ruel M; Fremes SE
Circ Cardiovasc Qual Outcomes; 2019 Dec; 12(12):e006017. PubMed ID: 31822120
[TBL] [Abstract][Full Text] [Related]
6. Fragility of Results in Ophthalmology Randomized Controlled Trials: A Systematic Review.
Shen C; Shamsudeen I; Farrokhyar F; Sabri K
Ophthalmology; 2018 May; 125(5):642-648. PubMed ID: 29241744
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
8. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
9. The fragility of statistically significant findings from randomized trials in head and neck surgery.
Noel CW; McMullen C; Yao C; Monteiro E; Goldstein DP; Eskander A; de Almeida JR
Laryngoscope; 2018 Sep; 128(9):2094-2100. PubMed ID: 29683494
[TBL] [Abstract][Full Text] [Related]
10. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
[TBL] [Abstract][Full Text] [Related]
11. The fragility of statistically significant results from clinical nutrition randomized controlled trials.
Pędziwiatr M; Mizera M; Wysocki M; Małczak P; Stefura T; Gajewska N; Torbicz G; Droś J; Kacprzyk A; Major P; Kłęk S; Bała M
Clin Nutr; 2020 Apr; 39(4):1284-1291. PubMed ID: 31221372
[TBL] [Abstract][Full Text] [Related]
12. The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey.
Evaniew N; Files C; Smith C; Bhandari M; Ghert M; Walsh M; Devereaux PJ; Guyatt G
Spine J; 2015 Oct; 15(10):2188-97. PubMed ID: 26072464
[TBL] [Abstract][Full Text] [Related]
13. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
14. The fragility of findings of randomized controlled trials in shoulder and elbow surgery.
Ruzbarsky JJ; Rauck RC; Manzi J; Khormaee S; Jivanelli B; Warren RF
J Shoulder Elbow Surg; 2019 Dec; 28(12):2409-2417. PubMed ID: 31420227
[TBL] [Abstract][Full Text] [Related]
15. How robust are clinical trials in heart failure?
Docherty KF; Campbell RT; Jhund PS; Petrie MC; McMurray JJV
Eur Heart J; 2017 Feb; 38(5):338-345. PubMed ID: 27742808
[TBL] [Abstract][Full Text] [Related]
16. The fragility index in randomized clinical trials supporting clinical practice guidelines for acute coronary syndrome: measuring robustness from a different perspective.
Gonzalez-Del-Hoyo M; Mas-Llado C; Blaya-Peña L; Siquier-Padilla J; Peral V; Rossello X
Eur Heart J Acute Cardiovasc Care; 2023 Jun; 12(6):386-390. PubMed ID: 36882068
[TBL] [Abstract][Full Text] [Related]
17. Fragility Index in Cardiovascular Randomized Controlled Trials.
Khan MS; Ochani RK; Shaikh A; Usman MS; Yamani N; Khan SU; Murad MH; Mandrola J; Doukky R; Krasuski RA
Circ Cardiovasc Qual Outcomes; 2019 Dec; 12(12):e005755. PubMed ID: 31822121
[TBL] [Abstract][Full Text] [Related]
18. The Fragility Index in Randomized Clinical Trials as a Means of Optimizing Patient Care.
Tignanelli CJ; Napolitano LM
JAMA Surg; 2019 Jan; 154(1):74-79. PubMed ID: 30422256
[TBL] [Abstract][Full Text] [Related]
19. Frequent fragility of randomized controlled trials for HCC treatment.
Zhang H; Li J; Zeng W
BMC Cancer; 2021 Apr; 21(1):389. PubMed ID: 33836710
[TBL] [Abstract][Full Text] [Related]
20. The Reproducibility of Cerebrovascular Randomized Controlled Trials.
Adeeb N; Terrell DL; Whipple SG; Thakur JD; Griessenauer CJ; Adeeb A; Aslan A; Mamilly A; Mortazavi MM; Dossani RH; Guthikonda B; Ogilvy CS; Thomas AJ; Moore JM
World Neurosurg; 2020 Aug; 140():e46-e52. PubMed ID: 32437984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
